6-K 1 a9604p.htm HISTORIC PROFORMA CATEGORY FINANCIAL PERFORMANCE a9604p
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of July 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F ☒
 
Form 40-F ☐
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
07 July 2025 - “Historic Proforma Category Financial Performance”
 
 
99.1
 
 
 
 
Haleon plc: Historic Proforma Category Financial Performance
 
7 July 2025: Haleon plc (the "Company" or "Haleon") today releases the historical proforma category financial information, aligned with the announcement at the Capital Markets Day on 1 May 2025. Haleon will now be reporting six categories: Oral Health; Vitamins, Minerals, and Supplements (VMS); Pain Relief; Respiratory Health; Digestive Health; and Therapeutic Skin Health and Other.
 
Compared to previous reporting, the new structure:
 
●
  Splits out Digestive Health & Other into Digestive Health, and Therapeutic Skin Health and Other
●
  Smokers Health which had previously been reported as part of Digestive Health and Other will now be included in Respiratory Health
●
  There are no changes to other categories not outlined above
 
We will begin reporting in this new category structure at our 2025 Half Year Results on 31 July 2025. The purpose of this change is to better align Haleon's reporting with the strategic opportunities ahead as well as improve visibility of Haleon's financial performance. Haleon's geographical split remains unchanged.
 
Detailed below is the quarterly pro-forma actual and comparative financial information on this basis. Definitions for non-IFRS measures can be found on pages 19-27 in Haleon's 2024 Full Year Results, and pages 43-50 in Haleon's Annual Report and Form 20-F 2024.
 
Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and reported revenue growth by category (unaudited)
 
 
2023
 
2024
 
£m revenue
Organic Revenue Growth
Reported Revenue Growth
 
£m revenue
Organic Revenue Growth
Reported Revenue Growth
Oral Health
3,136
10.6%
6.1%
 
3,312
9.6%
5.6%
VMS
1,640
0.9%
-2.1%
 
1,696
7.6%
3.4%
Pain Relief
2,652
7.4%
4.0%
 
2,564
0.1%
-3.3%
Respiratory Health
2,244
11.7%
8.2%
 
2,122
1.0%
-5.4%
Digestive Health
1,012
5.8%
1.9%
 
1,029
5.5%
1.7%
Therapeutic Skin Health and Other
618
8.8%
1.5%
 
510
9.8%
-17.5%
TOTAL
11,302
8.0%
4.1%
 
11,233
5.0%
-0.6%
 
 
Restated quarterly reported revenue by category (unaudited)
 
 
 
 
 
 
 
 
 
2023
 
2024
 
2025
£m
Q1
Q2
Q3
Q4
FY
 
Q1
Q2
Q3
Q4
FY
 
Q1
Oral Health
    811
    778
    790
    757
   3,136
 
    854
    829
    810
    819
   3,312
 
    880
VMS
    405
    411
    410
    414
   1,640
 
    422
    435
    407
    432
   1,696
 
    416
Pain Relief
    724
    681
    636
    611
   2,652
 
    662
    641
    628
    633
   2,564
 
    661
Respiratory Health
    638
    455
    563
    588
   2,244
 
    590
    454
    581
    497
   2,122
 
    525
Digestive Health
    259
    256
    234
    263
   1,012
 
    256
    264
    239
    270
   1,029
 
    254
Therapeutic Skin Health and Other
    149
    171
    165
    133
      618
 
    135
    152
    115
    108
      510
 
    117
TOTAL
 2,986
 2,752
 2,798
 2,766
 11,302
 
 2,919
 2,775
 2,780
 2,759
 11,233
 
 2,853
 
 
Restated quarterly organic revenue growth by category (unaudited)
 
 
 
 
2023
 
2024
 
2025
%
FY
 
Q1
Q2
Q3
Q4
FY
 
Q1
Oral Health
10.6%
 
10.6%
9.1%
8.2%
10.6%
9.6%
 
6.6%
VMS
0.9%
 
9.9%
8.5%
3.7%
8.2%
7.6%
 
0.9%
Pain Relief
7.4%
 
-4.8%
-4.0%
3.1%
7.4%
0.1%
 
2.6%
Respiratory Health
11.7%
 
-2.7%
1.3%
8.2%
-2.6%
1.0%
 
0.7%
Digestive Health
5.8%
 
2.2%
5.2%
9.0%
5.8%
5.5%
 
2.3%
Therapeutic Skin Health and Other
8.8%
 
7.4%
10.7%
0.7%
24.2%
9.8%
 
10.4%
TOTAL
8.0%
 
3.0%
4.1%
6.1%
6.8%
5.0%
 
3.5%
 
 
Restated quarterly reported revenue growth by category (unaudited)
 
 
 
 
 
2023
 
2024
 
2025
%
FY
 
Q1
Q2
Q3
Q4
FY
 
Q1
Oral Health
6.1%
 
5.3%
6.6%
2.5%
8.2%
5.6%
 
3.0%
VMS
-2.1% 
 
4.2%
5.8%
-0.7%
4.3%
3.4%
 
-1.4%
Pain Relief
4.0% 
 
-8.6%
-5.9%
-1.3%
3.6%
-3.3%
 
-0.2%
Respiratory Health
8.2% 
 
-7.5%
-0.2%
3.2%
-15.5%
-5.4%
 
-11.0%
Digestive Health
1.9% 
 
-1.2%
3.1%
2.1%
2.7%
1.7%
 
-0.8%
Therapeutic Skin Health and Other
1.5% 
 
-9.4%
-11.1%
-30.3%
-18.8%
-17.5%
 
-13.3%
TOTAL
4.1% 
 
-2.2%
0.8%
-0.6%
-0.3%
-0.6%
 
-2.3%
 
Enquiries
 
Investors
Media
 
Jo Russell
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
Emma White
+44 7823 523562
 
 
Email: investor-relations@haleon.com
Email: corporate.media@haleon.com
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com.
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: July 07, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary